Provectus Biopharmaceuticals Inc
provectusbio.comWhat Do They Do?
Develops rose bengal sodium-based immunotherapy drug candidates for patients with cancer, skin conditions, and eye diseases.
10-K for FY2025, filed Mar 26, 2026Provectus Biopharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, “Provectus” or “the Company”), is a…View ↗
Oncology: Intratumoral PV-10 has undergone and is undergoing multiple, monotherapy and combination therapy, early-to-late-stage clinical…View ↗
Dermatology: Topical PH-10, a formulation of PV-10, has undergone multiple mid-stage, monotherapy clinical trials for the treatments of…View ↗
Ophthalmology: The Company believes that clinical proof-of-concept (“POC”) of topical administration of non-pharmaceutical grade rose…View ↗
How Do They Make Money?
$336.1K
-
10-K for FY2025, filed Mar 26, 2026
$336.1K ↗
Do Revenues Turn Into Profits?
No. It lost $5.4M in FY2025.
10-K for FY2025, filed Mar 26, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$982.6KView ↗
- ▼ −46% (Loss)
- vs −$1.8M in Q2 FY2025
Shrinking. Revenue fell 66% in 3 years, from $989K in FY2022 to $336.1K in FY2025, about 30% a year.
Loading...
